1-2 of 2
Robert E. Brown
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies

Roman Groisberg, Jason Roszik, Anthony P. Conley, Alexander J. Lazar, Daniella E. Portal, David S. Hong, Aung Naing, Cynthia E. Herzog, Neeta Somaiah, Maria A. Zarzour, Shreyaskumar Patel, Robert E. Brown, Vivek Subbiah
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (5): 1165–1172.
https://doi.org/10.1158/1535-7163.MCT-19-0579
Published: 04 May 2020
View article titled, Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies
Open the PDF for Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies in another window
Journal Articles

Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist

Vivek Subbiah, Robert E. Brown, Jamie Buryanek, Jonathan Trent, Avi Ashkenazi, Roy Herbst, Razelle Kurzrock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (11): 2541–2546.
https://doi.org/10.1158/1535-7163.MCT-12-0358
Published: 08 November 2012
View article titled, Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
Open the PDF for Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist in another window